NCT01454986View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

October 31, 2013

Conditions
Healthy
Interventions
DRUG

ALXN1007

Single dose, IV

OTHER

Placebo

Single dose, IV

Trial Locations (1)

21225

PAREXEL Baltimore EPCU, Baltimore

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY